Home/HilleVax/Shane Maltbie

SM

Shane Maltbie

Chief Development Officer

Therapeutic Areas

Infectious Disease Gastroenterology

HilleVax Pipeline

Drug	Indication	Phase
HIL-214	Prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection	Phase 2b/3

Leadership Team at HilleVax

Chairman and Chief Executive Officer

Chief Financial Officer

A. Bruce Montgomery

Chief Medical Officer

Former Chief Medical Officer (key architect)

Tara Fitzgerald

Chief Technical Officer

View full HilleVax profile